Kymera Therapeutics vs Repligen

Kymera Therapeutics (KYMR), health care, and Repligen (RGEN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Kymera Therapeutics and Repligen are valued at about the same: $10.4B and $10.4B. Kymera Therapeutics's operating margin in its latest fiscal year was -891% and Repligen's 7.47%. Over the past year Kymera Therapeutics's share price has moved +95.7% and Repligen's +6.35%.

Key facts

Kymera Therapeutics market value
$10.4B
Repligen market value
$10.4B
Kymera Therapeutics revenue
$39.2MFY to 2025-12-31
Repligen revenue
$738.3MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Kymera Therapeutics vs Repligen: every measure side by side
Measure Kymera Therapeutics Repligen
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$10.4Bhigher$10.4Blower
Revenue$39.2Mlower$738.3Mhigher
Earnings-$311.4Mlower$48.9Mhigher
Employees285lower2,000higher
Total assets$1.7Blower$2.9Bhigher
Valuation
P/E——
P/S265higher14.0lower
P/B6.4higher4.4lower
Dividend yield0.00%0.00%
Profitability
Operating margin-891%lower7.47%higher
Balance sheet
Net assets$1.6Blower$2.1Bhigher
Total liabilities$163.1Mlower$843.6Mhigher
Total debt—$542.2M
Cash on hand$357Mlower$566Mhigher
Price change
Today-3.44%lower-0.37%higher
1 year+95.7%higher+6.35%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Kymera Therapeutics only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns KYMR · Who owns RGEN

Further comparisons

Learn

Questions and answers

Which is bigger, Kymera Therapeutics or Repligen?

By market value, Kymera Therapeutics is the larger: $10.4B against $10.4B for Repligen. By revenue in its latest fiscal year, Repligen is the larger: $738.3M against $39.2M for Kymera Therapeutics.

Which has the higher operating margin?

Repligen: 7.47%, against -891% for Kymera Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Kymera Therapeutics and Repligen?

None of the tracked superinvestors holds both in their latest 13F filing. 1 holds Kymera Therapeutics and 6 hold Repligen.

Cite this page

Funkfolio, “Kymera Therapeutics vs Repligen”, data as of 18 November 2026. https://funkfolio.com/compare/kymr-vs-rgen

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.